Breast cancer prognosis with relation to the human epidermal growth factor receptor-2 & hormonal status among women Mosul city – 2018

Abstract

Background: Breast cancer is the leading cause of death of women around the world. Rates differ by around fivefold across the globe, but they are rising in areas where the disease was previously uncommon. Aim  of  the  study:  the  aim  was  to  discover  whether  the  molecular classification of breast  cancer offers more knowledge about survival relative to traditional histopathological prognostic factors. Methodology: 
In this study, the prognostic influence of ER, PR, and HER2 expression was  analyzed  independently  in  breast  cancer  patients  using  an immunohistochemical study (n = 297) at Mosul Oncology Hospital in 2018  on  women  diagnosed  with  primary  breast  cancer,  and,  in combination,  survival  analysis  was  performed  using  age-adjusted Kaplan-Meier  and  Cox  relative  risk  models.  Patient,  Breast  Cancer Stage. 
Result: The results showed that patients (n=297) with different ER, PR, and HER2 expressions had different clinical outcomes with different treatment responses. Breast cancer's molecular classification was based on the pattern of expression of ER, PR, and HER2. The breast cancer subtype ER + / PR + / HER2 + was found in 36.3% of cases, ER + / PR + / HER2- observed in 23.9% of cases, ER - / PR- / HER2 + was observed in 23.5% of cases, and finally, a triple-negative subtype was found  in  16.16%  of  cases.ER+/PR+/HER2-  tumor  patients  have  a positive  prognosis,  while  triple-negative  adenoma  patients  have  the worst prognosis. We also suggest that this molecular classification be used to select the best treatment form in all breast cancer patients.